Clinical Trials Directory

Trials / Unknown

UnknownNCT00343668

S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer

A Phase II Study of S-1 and Irinotecan Combination Chemotherapy in Patients With Advanced Gastric Cancer as a First-Line Therapy

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
44 (estimated)
Sponsor
Korean Cancer Study Group · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The primary goal of this phase II trial is to evaluate the response rate of combination chemotherapy with S-1 and Irinotecan in patients with advanced gastric cancer as a first-line therapy.

Conditions

Interventions

TypeNameDescription
DRUGS-1, irinotecanS-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1

Timeline

Start date
2005-09-01
Primary completion
2007-03-01
Completion
2008-07-01
First posted
2006-06-23
Last updated
2010-05-26

Locations

7 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT00343668. Inclusion in this directory is not an endorsement.

S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer (NCT00343668) · Clinical Trials Directory